MCs are crucial regulators of the innate immune response. MC degranulation is a rapid response mechanism that allows for the release of a stored plethora of inflammatory mediators, including histamine, heparin, various serine proteases, chemokines, and cytokines. The activation of MCs can lead to the de novo expression of a variety of chemokines and cytokines that can influence a variety of outcomes: inflammation, angiogenesis, and others. A variety of IgE-independent mediators, including IgG, cytokines, chemokines, exogenous molecules, drugs, and cationic peptides, and others, can directly trigger MC activation. For decades, various peptide stimuli, including peptide toxins, neuropeptides, antimicrobial peptides, and endogenous bioactive peptides, have been associated with MC allergic reactions in various physiologic and pathologic conditions. Recently, an activation mechanism has been established, whereby the MRGPRX 2 receptor is involved in most of the peptide stimuli-related activation of human MCs. Interestingly, most of these peptide sequences seem to have a strong structural similarity that includes abundant positive charges and aromatic/aliphatic amino acids. In this review, we discuss the structures of known peptide stimuli and the receptors with which they interact for the express purpose of highlighting peptide elements as building blocks for tissue engineering applications.
Introduction
MCs are a part of the immune and neuroimmune system, play a key role in allergic inflammatory responses while participating in wound healing and angiogenesis, and are critical in mounting a host defense against pathogens [1] [2] [3] [4] . Immature MCs originate from the bone marrow and mature as they distribute throughout various connective tissues: skin, digestive tract, mucosa of lung and airways, and others. [5, 6] . Upon activation, MCs degranulate and rapidly release prestored mediators, including histamine, heparin, and multiple serine proteases, from their characteristic granules to the extracellular environment. De novo expression of inflammatory mediators, such as cytokines and chemokines, occurs when MCs experience stimulation [1] .
IgE/antigen-dependent MC activation is triggered by the antigen-induced cross-linking of Fce-RI on the membrane surface of the MC. However, MCs can also respond to a variety of IgEindependent mediators, such as IgG, cytokines, chemokines, pathogens, drugs, cationic peptides, and others [7] . In fact, a range of cationic peptides, including peptide toxins, neuropeptides, antimicrobial peptides, and endogenous bioactive peptides, has been associated with MC allergic reaction [7] [8] [9] [10] [11] .
MCs are not a homogeneous group of cells, and only certain subtypes within MC populations respond to peptide stimuli. For example, human b-defensins stimulate degranulation in rPMCs and the human MC line (LAD2) in vitro but do not induce degranulation in murine BMMCs [12] . One reason for the selectivity is that human MCs endogenously express GPCR: MRGPRX 2 , the ortholog of the mouse receptor; and Mrgprb2, which is a target of many peptides, including b-defensins; however, BMMCs do not express this receptor [12] .
The global peptide drug market is growing rapidly, with hundreds of synthetic therapeutic peptides currently in clinical development [13, 14] . Recently, the U.S. Food and Drug Administration has reported that the administration of a vast majority of peptide drugs is associated with allergic-type responses, such as ISR [15] . These peptides have been associated with the activation of a single MC receptor, MRGPRX 2 /Mrgprb2 (human/mouse), which leads to the release of histamine and various inflammatory substances [15] . Furthermore, through MC degranulation, several proteases are released into the surrounding tissue that could potentially degrade these peptide drugs and reduce their therapeutic efficacy. In addition to peptide drugs, an ever-increasing amount of tissue-contacting biomaterials (i.e., drug carriers, scaffolds, functional nanostructures, and coatings) is either composed of peptides/proteins or combined with bioactive peptides to achieve myriad therapeutic outcomes [16] [17] [18] . Specifically, potent peptide activators of connective tissue MCs, such as the antimicrobial peptide LL-37 [19, 20] and the neuropeptide SP [21] , have been used to impart implanted biomaterials with antimicrobial and angiogenic functionality, respectively. The identification of a general peptide domain responsible for activating MRGPRX 2 /Mrgprb2 would dramatically affect the development and application of peptide drugs by allowing for their prescreening, so as to prevent adverse side effects regardless of their delivery route-soluble bolus or incorporation into biomaterials.
In this review, we will discuss various reported peptide sequences that initiate MC activation, highlighting differences and similarities between those that interact with MRGPRX 2 / Mrgprb2 and other MC receptors. The structural similarities may guide us in discovering a generalized receptor recognition mechanism for MRGPRX 2 /Mrgprb2. A better understanding of the relationship between peptide structure and MC activation will benefit the design of peptide drugs and the development of peptide inhibitors of these receptors for alleviating allergic side effects or predict potential allergic side effects of engineered peptides and proteins.
PEPTIDE STIMULI

Peptide toxins
Mastoparan and other wasp venom-derived peptides. Mastoparan is a nonspecific secretagogue that stimulates different types of mammalian cells and is a peptide toxin derived from wasp venom. Earlier studies have demonstrated that mastoparan induces histamine release from rPMCs [22, 23] . Recently, mastoparan-induced human MC activation has been shown to be MRGPRX 2 mediated [15] . However, earlier literature suggests that mastoparan also increases the GTPase activity and thus, increases the amount of active G proteins [24, 25] . Therefore, mastoparan may also stimulate the G protein pathway independently of a receptor, which may explain how it is able to activate platelets and chromaffin cells that do not express MRGPRX 2 [24, 26] .
Like mastoparan, cationic peptides, derived from the venom of other wasp species, were evaluated to see if they initiated MC degranulation, including mastoparan-B, from the black-bellied hornet [27] , mastoparan-AF from the solitary wasp in Japan [28] , and protonectin and agelaia-MP from the neotropical social wasp [29] . Similar to mastoparan, mastoparan-B, mastoparan-AF, protonectin, and agelaia-MP are rich in hydrophobic and basic amino acids and exhibited similar activity in inducing the degranulation of mPMC, rPMC, and RBL 2H3 [15, 28, 29] .
Pilosulin 5. Pilosulin 5 is another kind of arthropod peptide toxin, which is derived from the venom of the Australian ant, Myrmecia pilosula, whose sting is a frequent cause of insect allergy in southeast Australia [30] . Pilosulin 5 is rich in basic and hydrophobic amino acid residues, which induces a dosedependent histamine release from rPMCs [31] ; the activation mechanism of the peptide remains ill defined.
Echinometrin. Some marine animals can also secrete peptide toxins that affect MCs. Echinometra lucunter is a common sea urchin found in Brazil, whose spines can induce an inflammatory reaction in skin through both mechanical trauma and toxic effects. In 2014, echinometrin was isolated and shown to trigger the in vivo degranulation of mouse mesentery MCs in a doseresponse manner [32] . Although the receptor for echinometrin has not been identified, it is thought that a GPCR may mediate its stimulation of MCs, as this is the mechanism seen for other dosedependent degranulating peptides from bee and wasp venom [32] .
Helodermin. Helodermin is a biologically active peptide isolated from the salivary gland venom of the Gila monster lizard, which has structural and functional similarities to mammalian VIP [33] [34] [35] . Like VIP, helodermin can induce MC activation and degranulation, which has been thought to contribute to the pathology of Gila monster envenomation [36] [37] [38] . However, recent evidence indicates that MCs may enhance host survival when exposed to these venoms through degradation of the helodermin by MC-derived proteases [36, 39] . Although it seems that helodermin may share the same pathway as VIP, the receptor that binds helodermin on MCs has not been reported.
Sarafotoxins. Sarafotoxins (A, B, and C) are a group of 21-residue toxic peptides isolated from snake venom that shows striking structural similarities to endothelins [40] [41] [42] . These peptides belong to the endothelin/sarafotoxin family, which are recognized by innate endothelin receptors, such as ET A , that are expressed on MC surface [40] . Sarafotoxin-B (or sarafotoxin 6b) is a major toxin isolated from Israeli mole viper venom and has been reported to induce MC degranulation in mice [43] . In addition, reports show that MC-derived proteases, especially CPA, can enhance the resistance to the toxicity of endothelin-1 or sarafotoxins by protease degradation [40, 43] .
Neuropeptides
SP. MCs are usually found in close proximity to nerves and thus, likely encounter high concentrations of neuropeptides. The close contact between activated MCs and nerves has been found at sites of inflammation in a variety of different tissues [44] [45] [46] . SP is an important neuropeptide that belongs to the tachykinin neuropeptide family. It has been reported to stimulate MC degranulation and cause chemokine and inflammatory cytokine release [47] . SP-mediated MC activation might be involved in stress-induced or neuronal inflammatory diseases [47, 48] , such as complex regional pain syndrome [49] . For years, it has been reported that SP and its N-terminal truncation sequences SP (2-11) and SP (3-11) stimulate a wide variety of MC populations, including rPMC [10, 22, 50] , mPMC [15] , LAD2 [47, 51] , rSMCs [49, 52] , hSMCs [50] , and hCBMCs [53] . Earlier studies have indicated the SP-mediated activation of rodent MCs is through NK1R [54, 55] ; however, recent findings suggested that stimulation of human MCs by SP is mediated by MRGPRX 2 [15, 53] . It is likely that activation can occur through a combination of these receptors, and this combination could be different in certain pathologies, such as allergic rhinitis or atopic dermatitis, where the expression of these receptors changes [52, 56, 57] . In addition, recent evidence indicates that SP activates human skin-derived cultured MCs through MRGPRX 2 but not through NK1R, which is also expressed by hSMCs [58] . Interestingly, the EC 50 of SP for NK1R and MRGPRX 2 is 0.5 and 100 nM, respectively; namely, NK1R is more sensitive to SP than MRGPRX 2 [59] . However, the absolute number of each receptor expressed on an MC may not be the same. A recent genetic study showed clearly that one of the most expressed receptors in the SMC transcriptome is the MRGPRX 2 receptor, even higher than the Fce-RI [60] . As SMCs express very tiny amounts of NK1R, it is only logical that any ligands that may bind to both, will likely bind more to MRGPRX 2 than NK1R.
Neurotensin. Neurotensin is a 13 aa neuropeptide secreted under stress in various tissues [51] and is involved in some skin disorders by inducing SMC degranulation [52] . It stimulates rodent MCs and causes histamine release through the NTR [61, 62] . It has been reported that neurotensin-triggered human MC (LAD2) degranulation significantly enhanced the corticotropinreleasing hormone-induced VEGF release through NTR. The activation can be blocked by the nonpeptide neurotensin antagonist SR48692 [51] . Moreover, neurotensin can be degraded rapidly by MC proteases, which implies that MCs regulate the activity of neurotensin through NTR-mediated degranulation [63, 64] .
Somatostatin. Somatostatin, also known as growth hormoneinhibiting hormone, is a multifunctional neuropeptide that is widely distributed over the CNS and peripheral tissues [65] . Somatostatin has been shown to be an agonist compound for MRGPRX 2 , which has induced concentration-dependent increases in the intracellular calcium concentration (Ca 2+ ) in MRGPRX 2 -expressing cells [53, 66] that lead to the activation and degranulation of various kinds of MC populations, including rPMC, hSMC, and hCBMC [50, 53, 67] .
Cortistatin-14. Cortistatin-14 is a neuropeptide localized within the cortex and hippocampus, which has several biologic functions, including sleep modulation, depression of neuronal activity, regulation of locomotor activity, and cortical function [66, 68] . Cortistatin-14 has a strong structural similarity to somatostatin and belongs to the somatostatin neuropeptide family. It binds to all known somatostatin receptors and shares many pharmacological and functional properties with somatostatin [69] . Like somatostatin, it was identified as the strong agonist for MRGPRX 2 [15, 53, 66] and induces degranulation of multiple types of MC populations (mPMC [15] , LAD2 [70] , hCBMC [53] ).
VIP. VIP is a 28 aa neuropeptide that belongs to a glucagon/ secretin superfamily [71] . VIP is produced in many tissues and plays roles in a wide variety of biologic activities, including systemic vasodilation, hyperglycemia, smooth muscle relaxation, hormonal regulation, analgesia, hyperthermia, and others [72] . Previous studies have demonstrated that human MCs express surface VPAC2 but not VPAC1, where IgE-mediated activation of human MCs up-regulate the expression of VPAC2 [47] . However, there is evidence that shows that the effect of PACAP or VIP on MCs is not mediated through VPAC2 [11] . Recently, it has been indicated that the dose-dependent, VIP-induced degranulation of human MCs is MRGPRX 2 mediated [53] . As one of the most studied neuropeptides, VIP has been reported as a degranulation or activation stimulus for various MC populations, including LAD2 [47] , rPMC [50] , hCBMC [53] , and hSMC [50] .
PACAP. PACAP is a neuropeptide similar to VIP, which has multiple functions, such as the regulation of metabolism, cardiovascular, endocrine, and immune systems [73, 74] . PACAP is known to induce histamine release in hSMCs [11] and induce the activation of various other MC populations, including hCBMC [53] , rPMC [75] , and rDMCs [75] , although it has been reported that PACAP and VIP share at least 3 GPCRs: polypeptide type 1 receptor, VPAC1, and VPAC2 (human MC) receptors [76] . However, PACAP-mediated activation of MCs does not occur through VPAC2 [11] . Like VIP, PACAP is a potent ligand for MRGPRX 2 and causes a dose-dependent degranulation of human MCs [53] .
Antimicrobial peptides LL-37. LL-37 is the only human member of the cathelicidin peptide family. It is a multifunctional antimicrobial peptide that promotes inflammation, angiogenesis, wound healing, and tumor metastasis [77, 78] . A variety of MC populations can be activated by LL-37, including rPMC [79, 80] and LAD2 [70, 81] . Although FPRL1 is the LL-37 receptor for neutrophil and monocyte migration, evidence of a competitive binding assay showed that LL-37-induced MC chemotaxis is unlikely to use the FPRL1 receptor [79] . Recently, it has been identified that LL-37 induces human MC chemotaxis, degranulation, and chemokine production via MRGPRX 2 , in dose-dependent manner [70] .
Catestatin. Catestatin is a neuroendocrine peptide derived from the prohormone chromogranin A, which has recently been found to be an antimicrobial peptide in human skin. It is reported to perform antimicrobial activity against a wide range of pathogens in human skin, including bacteria, yeast, and fungi [9, 82] . Catestatin can induce LAD2 activation and may link neuroendocrine and cutaneous immune systems [9] . It also induces the release of histamine from rPMC, and the potency and efficacy of catestatin (EC 50 : 0.6 mM) is higher than the wasp venom peptide mastoparan (EC 50 : 2.6 mM) and SP (EC 50 : 3.0 mM) [23] .
Indolicidin. Indolicidin is an antimicrobial peptide, originally purified from the cytoplasmic granules of bovine neutrophils. This peptide exhibits activity against both Gram-positive and -negative bacteria and fungi [83] . The sequence of indolicidin has an unusually high mole percent of W compared with other known protein sequences. The multiple W residues of the peptide may play an important role in its antibacterial activity [84] . It was found that as other cationic antimicrobial peptides, indolicidin increased the intracellular calcium concentration (Ca 2+ ) in MRGPRX 2 -expressing cells and causes dose-dependent degranulation of human MCs (hCBMCs) [53] .
b-Defensins. b-Defensins are a family of cationic antimicrobial peptides found in mammals [85] . It was reported that human b-defensin 2, but not b-defensin 1, induced histamine release by increasing intracellular calcium concentrations (Ca 2+ ) of rPMCs and that this was more potent than LL-37 [80] . Like b-defensin 2, b-defensins 3 and 4 can also induce the activation of various MC populations, including rPMC [12, 23, 86] , LAD2 [8, 9, 12, 81, 86] , and hSMCs [81] . The receptor for b-defensins in MCs was originally described as a GPCR [86, 87] , specifically using the G protein-phospholipase C signaling pathway [87] . b-Defensins 2 and 3 do not induce degranulation of murine BMMCs that do not express MRGPRX 2 but activate the basophilic cell line RBL-2H3 and murine BMMCs transfected with MRGPRX 2 [12] .
Pleurocidin. Pleurocidins are a novel family of a-helical cationic antimicrobial peptides that were originally identified in various Atlantic flounder species [88] . These peptides share similar structure and functions with cathelicidins and have broadspectrum activity toward bacteria, fungi, parasites, and enveloped viruses [89, 90] . Some pleurocidins have been proven to be capable of effectively inducing degranulation and the release of proinflammatory mediators from LAD2 via FPRL1, whereas others do not (sequences are not shown in Table 1 ) [8] .
Other endogenous bioactive peptides PAMP (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) . PAMP (1-20) (also known as PAMP-20) is a 20 aa hypotensive peptide expressed in the adrenal medulla that has been shown to induce a dose-dependent histamine release from rPMC [91] . PAMP (9-20) (also known as PAMP-12) is the C-terminal region of PAMP (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) , which was identified as an endogenous peptide derived from an adrenomedullin precursor with significant biologic activity [99] . PAMP (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) was also identified as an endogenous ligand for MRGPRX 2 [66, 100] and has been shown to induce MC activation through MRGPRX 2 [15] . The activity difference of PAMP (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) and PAMP (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) at the MRGPRX 2 receptor has been reported: the relative activity of PAMP (1-20) has 45.9 6 4.5% of the activity of PAMP (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) [101] .
Kallidin and bradykinin. Kallidin and bradykinin are bioactive kinins that play an important role in inflammation and cardiovascular function. They share a very similar structure, and kallidin can be converted to bradykinin via the aminopeptidase enzyme [102] . Kallidin and bradykinin cause a histamine release from rat MCs, where kallidin is much more potent than bradykinin [10] . Recent research indicated that kallidin induced MC (mPMC) activation through MRGPRX 2 /Mrgprb2 receptors [15] .
Endothelin-1. Endothelin-1 is a potent peptide vasoconstrictor, produced by vascular endothelial cells, which is critical to vascular homeostasis and participates in the development of several types of vascular disease: hypertension, atherosclerosis, and vasospasm after subarachnoid hemorrhage [103] . Endothelin-1 is known to be one of the most potent histamine releasers in mPMC [93] , and it also induces the activation of various other MC populations, including mouse fetal SMCs, rPMC, mBMMC, through ET A [94] [95] [96] . Evidence shows that ET Adependent MC activation can diminish both endothelin-1 levels and endothelin-1-induced pathology in vivo via releasing proteases that degrade endothelin-1 [104] .
SLIGKV-NH 2 . A synthetic peptide (SLIGKV-NH 2 ), based on the N-terminal domain of itch-related human PAR2, which has been used as a specific agonist for PARs, was also found to activate MRGPRX 2 [97] . An earlier report shows that SLIGKV-NH 2 can induce dose-dependent release of tryptase and histamine from human colon MCs [98] .
Peptide drugs
Besides natural peptide stimuli, a series of peptide drugs, including icatibant, cetrorelix, octreotide, leuprolide, and others, containing artificial or modified amino acids, are also known agonists for MRGPRX 2 that can induce MC activation and ISRs [15] . Interestingly, a large proportion of those modified residues are hydrophobic (aromatic and aliphatic) or positively charged. These structural features correspond to the described similarity between peptide ligands for MRGPRX 2 .
MC RECEPTORS DIRECTLY STIMULATED BY PEPTIDES
Recent evidence indicates that IgE/antigen-dependent and peptide (i.e., SP, endothelin-1, and others)-induced MC activation results in distinct patterns of granule secretion. IgE/antigendependent degranulation is associated with a sustained release of larger and more heterogeneously shaped granule structures, whereas SP-activated MCs rapidly secrete small and relatively spherical granule structures [105] . These differences, combined with differences in the de novo expression of MC mediators upon stimulation, may contribute to the observed differences in MCdependent inflammation; where pseudoallergic skin reactions of peptide drugs (mostly through MRGPRX 2 /Mrgprb2 [15] ) are often transient (e.g. icatibant [106] ), conversely, IgE-dependent skin reactions are usually sustained and result in more persistent local inflammation [107] .
MRGPRX 2 /Mrgprb2
MRGPRX 2 is a protein receptor expressed in sensory neurons and human MCs. It is the only member of the MRGPR family shown to be expressed outside of the nervous system [108, 109] . That is, connective tissue MCs are the only cells, outside of neurons, that express MRGPRX 2 [15] . The specificity of MRGPRX 2 expression to these cells suggests that this is somehow important in MC/neuron interactions, which connect the nervous and innate immune systems. Furthermore, the most expressed receptor in SMCs is MRGPRX 2 , even higher than the Fce-RI [60] . Mrgprb2 is the mouse ortholog of human MRGPRX 2 [15, 100] . It is a nonselective receptor that can be triggered by different peptides or some small-molecule drugs and causes MC degranulation and the release of inflammatory factors [15] . Moreover, it is worth noting that Mrgprb2 and MRGPRX 2 have been shown not to be exactly the same. Neurokinins and NK1R LAD2 [47] , rPMC [50] , hCBMC [53] hSMC [50] (continued on next page) contribute to the development of allergic responses in mice, but antagonists to NK1R had no effect on human subjects in clinical trials. Recent evidence has indicated that conventional NK1R antagonists (L733060 and aprepitant) have off-target activity of SP on Mrgprb2 but not on MRGPRX 2 [59] . In addition, the EC 50 of SP for human MRGPRX 2 is ;150 nM, whereas the EC 50 of SP for mouse Mrgprb2 is ;50 mM, which means that MRGPRX 2 is 100 times more sensitive to SP than Mrgprb2 [15] . The similar results have been confirmed by a number of other peptide ligands for Mrgprb2 and MRGPRX 2 (Table 1) [15] . As shown in Table 1 , the shared property of the peptides that activate MCs through MRGPRX 2 /Mrgprb2 is that their sequences contain amino acids with hydrophobic and positively charged residues. Knockout mice that do not express this Mrgprb2 exhibited attenuated allergic symptoms when challenged with an allergen compared with wild-type mice challenged with the same allergen [15] . Therefore, MRGPRX 2 has been proposed to be an important drug target to alleviate the side effects caused by myriad peptide drugs [15] .
Recently, a tripeptide NK1R antagonist, QWF (see supporting materials in Supplemental Fig. 1A ), has been shown to block the binding of SP to both Mrgprb2 and MRGPRX 2 and inhibits nonIgE-mediated MC degranulation, whereas NK1R antagonists L733060 and aprepitant affect Mrgprb2 but not MRGPRX 2 [59] , implying that aromatic amino residues and aliphatic groups (i.e., Boc-) are important for ligand binding to Mrgprb2 and MRGPRX 2 . It seems that QWF may have a therapeutic potential, as a result of its antagonism of NK1R and MRGPRX 2 ; however, it has also been reported that the tripeptide is rapidly metabolized in plasma, which limits its efficacy [59, 110] . Thus, a stable and specific MRGPRX 2 antagonist still needs to be discovered.
The identification of the pharmacophore elements, namely, the key amino acid residues of each peptide ligand that is involved in the biologic activity, is the first step to design peptide agonists and antagonists [111] . However, the structure activity relationship of peptide agonists of MRGPRX 2 has not been fully studied. Although the core structures of PAMP (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) and cortistatin-14 have been suggested to be "WxxWxxxR" and "WxxFxxxK," respectively, there is still a dearth of information regarding the minimal active sequence and the effect of amino acid composition for position "x" in this sequence [101] . In addition, the investigation of core structures of other potent peptide agonists would help in understanding the recognition mechanism of the MRGPRX 2 receptor.
ET A receptor
ET A is a human GPCR that is largely expressed in VSMCs, where they are responsible for vasoconstriction [112] . However, ET A receptors have also been found in many cell types other than VSMCs, such as neurons, hepatocytes, osteoblasts, adipocytes, and others [113] . Various MC populations express ET A , which can be activated by sarafotoxin-B or endothelin-1 [43, [93] [94] [95] , and lead to the release of proteases that degrade sarafotoxin-B and endothelin-1. Apparently, the selectivity of ET A receptors on MCs is much higher than MRGPRX 2 /Mrgprb2, and the peptide structure of ET A ligands that induce MC activation is different from MRGPRX 2 / Mrgprb2 ligands. Although there are hydrophobic and positively charged amino acids in these sequences, the net charge of endothelin-1 and sarafotoxin-B is negative overall.
NK1R
NK1R is a GPCR, widely distributed throughout the immune and nervous system. NK1R is a highly conserved receptor; the endogenous ligand for this receptor is SP [114] . Previous studies have shown that SP initiates rodent MC degranulation and chemokine production though NK1R [54, 55] . However, other studies show that SP-induced MC activation is at least partly mediated by MRGPRX 2 /Mrgprb2 [15, 53, 66] . In addition, research using knockout (NK1R-deficient) mice indicate that SP-induced inflammation is an MC-dependent but NK1R-independent mechanism [115] . Fujisawa et al. [58] , recently showed that SP selectively activates human skin-derived cultured MCs via MRPGRX 2 , not NK1R. It is worth noting that not all types of MCs express MRGPRX 2 . Thus, we speculate that some MCs may respond to SP stimulation via NK1R, if they do not (or minimally) express MRGPRX 2 .
NTR
NTR was identified on MCs more than one decade ago [61, 62] . It has been reported that SR48692, an antagonist of the brain NTR, inhibits neurotensin-mediated MC secretion but not stimulation via SP, bradykinin, or compound 48/80 [116] .
FPRL1
FPRL1 is a 7-transmembrane domain GPCR, which is involved in host defense against bacterial infection and in the clearance of damaged cells [117] . Human MCs express FPRL1, and the pleurocidin-mediated activation of LAD2 can be inhibited by pretreatment with FPRL1-specific inhibitor WRW4 [8] . However, it should be noted that the inhibition is limited, as only one-half of the degranulation activity has been inhibited after 2 h incubation with 1 mM WRW4, which means that there could be other activation mechanisms besides the FPRL1 pathway.
THE STRUCTURAL SIMILARITY OF PEPTIDE LIGANDS
The length of peptide ligands listed in Table 1 is relatively short (8-45 residues); thus, peptide ligand structures are limited to primary and secondary structures. In particular, most of the peptide stimuli listed share a similar sequence that largely includes positively charged (K and R), aromatic (F, Y, and W), and aliphatic (A, V, I, L, and M) amino acids. The net charge of these peptide sequences at pH 7.0 is commonly positive, where ET A ligands (i.e., endothelin-1 and sarafotoxin-B) are the exception and are negatively charged. In addition, aromatic residues (F, Y, and W) are not present in the sequences of some invertebrate toxic peptides, such as mastoparan, mastoparan-AF, protonectin, echinometrin, and the PAR2 agonist SLIGKV-NH 2 . However, those peptides still contain a high proportion of other hydrophobic amino acids, including A, L, I, V, and M, which possess aliphatic side chains.
Peptide truncation studies have been used to elucidate the importance of these amino acids in peptide ligands for MRGPRX 2 /Mrgprb2. For example, the structure activity relationship of PAMP and cortistatins for the MRGPRX 2 receptor has been described, where the addition of negatively charged amino acids (D and E) at the N-termini led to a marked decrease in efficacy (Supplemental Table 1 ) [66, 101] . Meanwhile, the further truncated PAMP (16) (17) (18) (19) (20) resulted in total loss of activity, which illustrated the importance of the with no K motif (Supplemental Table 1 ). Another example of the degranulation activity of SP and its truncated sequences for LAD2 can indirectly indicate the key role of positively charged amino acids in receptor recognition. Recent evidence has shown that SP induced histamine release from hSMCs through MRGPRX 2 activation [58] . Thus, we can speculate that the positively charged amino acid (R and/or K) was essential for MRGPRX 2 recognition. In addition, as mentioned in MRGPRX 2 /Mrgprb2 above, it has recently been reported that an NK1R antagonist, QWF, blocked the binding of SP to both Mrgprb2 and MRGPRX 2 [59] . The structure of the modified tripeptide QWF is shown in Supplemental Fig. 1 and contains a hydrophobic N-terminal "Boc-" group; 2 aromatic residues, "D-Trp(For)" and "-Phe"; and an aromatic C-terminal "-OBzl" group. This structure also confirmed the importance of aromatic/hydrophobic residues in MRGPRX 2 /Mrgprb2 recognition. Interestingly, those structures, namely, positively charged and aromatic/hydrophobic motifs, also exist in nonpeptide MRGPRX 2 /Mrgprb2 ligands (Supplemental Fig. 1B) . It has been reported that drugs containing a tetrahydroisoquinoline motif with quaternary ammonium cations (e.g., atracurium, tubocurarine, and others) or a bulky hydrophobic group with a charged nitrogen (rocuronium) induce MC activation through MRGPRX 2 [15] . Compound 48/80, a classic agonist of the MRGPRX 2 /Mrgprb2 receptor, is a polymeric base possessing secondary amino groups whose dissociation constant lies close to 9.0 and is positively charged in physiologic conditions [15, 118] . Its monomer contains a hydrophobic benzene ring and 2 terminal methyl groups that correspond to the described peptide ligand similarity. However, ligands, such as rocuronium, SLIGKV-NH 2 , and mastoparan, do not contain aromatic structures but other hydrophobic groups, suggesting that aromatic residues alone may not be necessary for MRGPRX 2 /Mrgprb2 recognition. Moreover, the potency of rocuronium to activate MRGPRX 2 is lower than compound 48/80 and atracurium, and mastoparan also possess less potency to MRGPRX 2 than PAMP (9-20), SP, and cortistain-14 that contain aromatic residues (see Supplemental Fig. 1 [15] ). Those results suggest that the aliphatic groups may partly replace the role of the aromatic rings but result in a lower binding affinity to MRGPRX 2 .
Secondary structures, in some cases, were predicted for peptide ligands based on data obtained from the PDB database. As shown in Fig. 1 , most ligands of MRGPRX 2 /Mrgprb2 contain a high a-helix content (53-86%), whereas b-defensins have a lower a-helix content (11-14%). The only exceptions seem to be the small peptide somatostatin and SP that have no a-helix structure. For ET A ligands, endothelin-1 and sarafotoxin-B have similar primary structures that result in lower amounts of a-helix secondary structures. As there is a lack of data for ligands, the structural similarities of NTR and FPRL1 are not easily generalized. It is worth noting that not only SP but other small molecule drugs can activate MRGPRX 2 /Mrgprb2, which suggests that the helix structure may not be necessary for receptor recognition (Supplemental Fig. 1 ) [15] . It has been indicated that some amino acids, such as M, A, L, E, and K, have especially high helix-forming propensities [119] and that they are frequently observed within these peptide stimuli. Thus, the helical structure may not be necessary for receptor binding but a natural result of the inclusion of these hydrophobic amino acids that bind this receptor.
It seems, based on the available peptide ligand data, that an MRGPRX 2 /Mrgprb2 receptor ligand may be primarily cationic with aromatic amino acids that largely adopt an a-helix formation. It is worth noting that cationic a-helical peptides are usually considered antimicrobial agents, such as b-defensins and LL-37 [120] [121] [122] . Moreover, many cationic a-helical peptides were widely used in biomaterials as carriers in gene delivery [123] [124] [125] and cell-penetrating peptides for drug delivery into cells [126, 127] . Thus, the potential side effect induced by the interaction between cationic a-helical peptides and MCs should be considered.
PEPTIDE DEGRADATION BY MC PROTEASES, A REGULATORY MECHANISM
In the previous section, the structural similarities in peptide ligands for the MRGPRX 2 /Mrgprb2 receptor were summarized. However, as mentioned, those peptides have very different origins, some are endogenous mediators, such as neuropeptides and antimicrobial peptides, or exogenous toxins from animal venoms. The biologic function of MRGPRX 2 /Mrgprb2-mediated activation of MCs is still unknown. However, we noticed that the sequence similarities of those peptide ligands match the cleavage specificities of MC proteases. Here, we propose a hypothesis that one biologic function of the activation of MRGPRX 2 /Mrgprb2 on the MC is to regulate the endogenous activator concentration or mitigate the effects of venom exposure. For example, the excess endogenous/toxic peptide stimuli in the local environment led to MC degranulation, namely, a fast release of prestored proteases, which may themselves degrade the peptides that actually activated the MCs (Fig. 2) .
MC proteases: type and function
MC degranulation is a process that releases a number of preformed granule compounds, including cytokines, histamines, and MC specific proteases [1] . In humans, the MC-specific proteases, chymases, tryptases, and CPA are major constituents of mature MC granules [128] . Chymases and tryptases belong to the serine protease family, whereas CPA is a zinc-dependent metallopeptidase that belongs to the zinc carboxypeptidase family. Chymases are chymotrypsin-like proteases that cleave peptide or protein sequences preferentially after the aromatic amino acid residues, with the order of preference as F . Y . W [129] . Tryptases have trypsin-like cleavage specificities; namely, they cleave peptide or protein sequences after the R or K residues. CPA is an exopeptidase that cleaves C-terminal aromatic or aliphatic amino acids [130, 131] . Interestingly, these cleavage specificities perfectly match the structural similarity of peptide ligands that showed a curious correlation between ligand recognition and peptide degradation.
Peptide stimuli degradation by MC proteases
As MC proteases have a broad cleavage specificity; they can digest a large number of proteins and peptides, such as extracellular matrix proteins and inflammatory substances [128] . Many peptide stimuli that cause MC degranulation have been identified as substrates for MC proteases ( Table 2 ). The in vivo digestion of endogenous or exogenous bioactive peptides by MCreleased proteases usually leads to their inactivation, limiting their toxicity and potentially regulating inflammation ( Fig. 2 and Table 2 ).
MC proteases may be a protective mechanism against venom toxicity that enhances the host's resistance. For example, the peptide toxins helodermine and sarafotoxin-B have been identified as a substrate of chymase [36] and CPA [40, 43] , respectively. Chymase can reduce the toxicity of helodermine, as well as the similar VIP, through degradation [36] . MCs can also diminish endothelin-1 level and endothelin-1-induced pathology, enhance the survival rate to sarafotoxin-B toxicity by removing the crucial W from the C-terminus, and promote homeostasis in vivo [40, 43, 104] . In addition, VIP and endothelin-1 can be degraded by tryptase [132, 133] and chymase [70, 89] , respectively. MC chymase can regulate psoriatic inflammation [132] and neurogenic inflammation [133] by cleaving SP. The neurotensin levels can be reduced by chymase [135] and CPA [130, 135] , and the MC-dependent reduction in neurotensin levels enhanced survival after sepsis [134] . LL-37 is known to be a potent antimicrobial agent that is abundantly expressed during inflammation. The physiologic concentrations of LL-37 induce MC degranulation and the release of MC proteases. The released tryptase can rapidly degrade LL-37 and initiates an effective feedback loop to limit LL-37 activity during inflammation [87] (example shown in Fig. 2 ). In addition, early work has shown that hypotensive peptides, kallidin and bradykinin, can be inactivated by chymase cleaving at the C-terminal "F-R" peptide bond [137] .
CONCLUSIONS AND FUTURE PERSPECTIVE
In this review, we found that the sequences of most of MRGPRX 2 /Mrgprb2 peptide ligands have several structural similarities: 1) abundant positive charges and aromatic/aliphatic amino acids and 2) usually rich in helical secondary structure. Moreover, we noticed that these peptide ligands are reported to be degraded by human MC-specific proteases, namely chymase, tryptase, and CPA, and the degradation was reported to be protective or a regulation progress. Interestingly, the cleavage specificities of these MC proteases are highly relevant to the structural features of MRGPRX 2 /Mrgprb2 peptide ligands. Therefore, the MRGPRX 2 /Mrgprb2 receptor on MCs may play the key role in the feedback loop toward protection of peptide toxins and regulation of bioactive peptides.
Mature MCs activated by peptide stimuli can release a variety of mediators that may induce a chain of host responses. Knowledge of the mechanisms responsible for peptide-induced MC degranulation is organized and discussed in this review, which may benefit future studies around designing peptide drugs so as to avoid potential side effects caused by their interaction with MCs. Specifically, the elucidation of the MRGPRX 2 structure will significantly advance our understanding of the molecular basis for ligand recognition and allow for the development of new inhibitors for MRGPRX 2 that may modulate the allergic reactions induced by peptide drugs. The structural similarities of peptide ligands provide a research foundation and template for antagonist screening, especially for the MRGPRX 2 receptor that dominants nonspecific, peptide-induced MC activation. The core motifs shared by different peptide ligands of MRGPRX 2 need to be identified. However, it's worth noting that some peptide ligands, such as SP, have redundant receptors; the inhibition of a single receptor may not be sufficient for modulating a pathologic condition. There is evidence that peptide characteristics, such as net charge and helical structure, are critical for the activity of peptides at the MRGPRX 2 receptor. Thus, one strategy for avoiding side effects of administered peptide drugs may be to redesign the sequence, such as extend the sequences with negative-charged residues, or design peptide prodrugs to avoid a positive net charge.
Beyond the allergic reaction of peptide drugs, the inhibition of MRGPRX 2 on MCs may also benefit the treatment of other diseases, such as tissue fibrosis, irritable bowel syndrome, and inflammatory dermatoses [57, [139] [140] [141] . On the other hand, MCmediated innate defense has been demonstrated to be protective. MCs are widely distributed in tissues that interface with the external environment and are filled with large amounts of preformed protective compounds, which is ideally to be regarded as a new target for immunotherapies for wound healing, angiogenesis, host defense against pathogens, toxins, and others. Enhance the host resistance to the toxicity [40] CPA [40, 43] Neuropeptides SP Regulate psoriatic inflammation [132] Chymase [132, 133] 
Neurotensin
Enhance survival by reduce neurotensin levels during sepsis [134] Chymase [135] , CPA [130, 135] VIP Limit the toxicity [36] Chymase [36, 132, 133] , tryptase [132, 133] Antimicrobial peptides
LL-37
Initiates an effective feedback loop to limit LL-37 activity during inflammation [136] Tryptase [136] Other endogenous bioactive peptides Kallidin Inactivate kallidin [137] Chymase [137] 
Bradykinin
Inactivate bradykinin [137] Chymase [137] Endothelin-1
Promote homeostasis and limit the toxicity [104] Chymase [104, 138] , CPA [40, 138] For example, the prestored and de novo-expressed VEGF from activated MCs is likely released so as to promote angiogenesis in ischemic tissue regions. It was reported that low-dose irradiation increases VEGF production by MCs and promotes vascular regeneration in an ischemic model [142] . However, relatively little research on how to mobilize MCs against toxins, pathogens, and infection or use them for augmenting wound healing and angiogenesis has been done. Therefore, the development of research in biomaterials and nanomedicine could provide a new platform to regulate MC activity via forming functionalized nanoparticles or matrices that can be easily combined with bioactive peptides for various therapies. Thus, the understanding of the peptide-receptor interaction should not just be regarded as being important only to understanding MC action in normal host responses, but this knowledge may also allow for the manipulation of MCs for immunotherapies. 
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